FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3200899174> ?p ?o ?g. }

• W3200899174 endingPage "100231" @default.
• W3200899174 startingPage "100231" @default.
• W3200899174 abstract "PARP inhibition may enhance antitumor responses in BAP1-associated mesothelioma by inducing synthetic lethality.A single-center, nonrandomized, phase 2 trial was conducted, in which patients with refractory mesothelioma were given olaparib 300 mg twice daily in a 21-day cycle until disease progression or intolerable toxicity. The primary objective was to determine the objective response rate on the basis of somatic or germline mutation status of DNA repair genes. The secondary objectives were to assess safety and tolerability and to determine progression-free survival (PFS) and overall survival (OS). Whole-exome sequencing was performed on blood and tumor.A total of 23 previously treated patients with pleural and peritoneal mesothelioma were enrolled and treated (germline BAP1, n = 4; germline MRE11A, n = 1; somatic BAP1, n = 8 mutations). There was one (4%) partial response, 18 (78%) with stable disease at 6 weeks, and four (17%) with progressive disease. The median overall PFS and OS were 3.6 months (95% confidence interval [CI]: 2.7-4.2 mo) and 8.7 months (95% CI: 4.7 mo-not estimable), respectively. The median PFS of germline BAP1 mutants (n = 4) was 2.3 months (95% CI: 1.3-3.6 mo) versus 4.1 months (95% CI: 2.7-5.5 mo) for wild-type (n = 19; p = 0.019). The median OS was 4.6 months (95% CI: 3.1-4.9 mo) for germline BAP1 mutation versus 9.6 months (95% CI: 5.5 mo-not estimable) in no germline mutation (p = 0.0040). Olaparib was safe with no new safety concerns.Olaparib has limited activity in previously treated mesothelioma including patients with BAP1 mutations. Germline BAP1 mutations were associated with decreased PFS and OS." @default.
• W3200899174 created "2021-09-27" @default.
• W3200899174 creator A5017638182 @default.
• W3200899174 creator A5017903894 @default.
• W3200899174 creator A5029872582 @default.
• W3200899174 creator A5039792443 @default.
• W3200899174 creator A5042829360 @default.
• W3200899174 creator A5044239219 @default.
• W3200899174 creator A5045973874 @default.
• W3200899174 creator A5048832124 @default.
• W3200899174 creator A5060745001 @default.
• W3200899174 creator A5074644543 @default.
• W3200899174 creator A5088472830 @default.
• W3200899174 creator A5090485561 @default.
• W3200899174 date "2021-10-01" @default.
• W3200899174 modified "2023-09-27" @default.
• W3200899174 title "Phase 2 Study of Olaparib in Malignant Mesothelioma and Correlation of Efficacy With Germline or Somatic Mutations in BAP1 Gene" @default.
• W3200899174 cites W1971419576 @default.
• W3200899174 cites W1973904343 @default.
• W3200899174 cites W1985393389 @default.
• W3200899174 cites W1999659306 @default.
• W3200899174 cites W2007265317 @default.
• W3200899174 cites W2007541023 @default.
• W3200899174 cites W2019607817 @default.
• W3200899174 cites W2022309076 @default.
• W3200899174 cites W2044271955 @default.
• W3200899174 cites W2056848326 @default.
• W3200899174 cites W2071818162 @default.
• W3200899174 cites W2096980867 @default.
• W3200899174 cites W2100576484 @default.
• W3200899174 cites W2102627969 @default.
• W3200899174 cites W2103441770 @default.
• W3200899174 cites W2104676123 @default.
• W3200899174 cites W2105287018 @default.
• W3200899174 cites W2131561057 @default.
• W3200899174 cites W2156267070 @default.
• W3200899174 cites W2158929973 @default.
• W3200899174 cites W2161560609 @default.
• W3200899174 cites W2165041092 @default.
• W3200899174 cites W2171972386 @default.
• W3200899174 cites W2277631374 @default.
• W3200899174 cites W2294633761 @default.
• W3200899174 cites W2329160730 @default.
• W3200899174 cites W2499615061 @default.
• W3200899174 cites W2597062310 @default.
• W3200899174 cites W2604785147 @default.
• W3200899174 cites W2621271973 @default.
• W3200899174 cites W2737389832 @default.
• W3200899174 cites W2740330777 @default.
• W3200899174 cites W2741664311 @default.
• W3200899174 cites W2897430921 @default.
• W3200899174 cites W2903799300 @default.
• W3200899174 cites W2938922501 @default.
• W3200899174 cites W2941506207 @default.
• W3200899174 cites W2947826965 @default.
• W3200899174 cites W3000700018 @default.
• W3200899174 cites W3004324761 @default.
• W3200899174 cites W3017413818 @default.
• W3200899174 cites W3029427435 @default.
• W3200899174 cites W3032665916 @default.
• W3200899174 cites W3047173080 @default.
• W3200899174 cites W3087416729 @default.
• W3200899174 cites W3122627530 @default.
• W3200899174 cites W3125643204 @default.
• W3200899174 cites W4293241248 @default.
• W3200899174 doi "https://doi.org/10.1016/j.jtocrr.2021.100231" @default.
• W3200899174 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8502774" @default.
• W3200899174 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34661178" @default.
• W3200899174 hasPublicationYear "2021" @default.
• W3200899174 type Work @default.
• W3200899174 sameAs 3200899174 @default.
• W3200899174 citedByCount "17" @default.
• W3200899174 countsByYear W32008991742022 @default.
• W3200899174 countsByYear W32008991742023 @default.
• W3200899174 crossrefType "journal-article" @default.
• W3200899174 hasAuthorship W3200899174A5017638182 @default.
• W3200899174 hasAuthorship W3200899174A5017903894 @default.
• W3200899174 hasAuthorship W3200899174A5029872582 @default.
• W3200899174 hasAuthorship W3200899174A5039792443 @default.
• W3200899174 hasAuthorship W3200899174A5042829360 @default.
• W3200899174 hasAuthorship W3200899174A5044239219 @default.
• W3200899174 hasAuthorship W3200899174A5045973874 @default.
• W3200899174 hasAuthorship W3200899174A5048832124 @default.
• W3200899174 hasAuthorship W3200899174A5060745001 @default.
• W3200899174 hasAuthorship W3200899174A5074644543 @default.
• W3200899174 hasAuthorship W3200899174A5088472830 @default.
• W3200899174 hasAuthorship W3200899174A5090485561 @default.
• W3200899174 hasBestOaLocation W32008991741 @default.
• W3200899174 hasConcept C104317684 @default.
• W3200899174 hasConcept C109825262 @default.
• W3200899174 hasConcept C121608353 @default.
• W3200899174 hasConcept C126322002 @default.
• W3200899174 hasConcept C13514818 @default.
• W3200899174 hasConcept C142724271 @default.
• W3200899174 hasConcept C143998085 @default.
• W3200899174 hasConcept C182979987 @default.
• W3200899174 hasConcept C197934379 @default.
• W3200899174 hasConcept C207103383 @default.

• next